Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 0.7% during trading on Wednesday . The stock traded as low as $7.35 and last traded at $7.41. 5,964,234 shares were traded during mid-day trading, a decline of 7% from the average session volume of 6,419,481 shares. The stock had previously closed at $7.46.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Trading Down 0.4 %

The firm has a market capitalization of $1.99 billion, a P/E ratio of -4.58 and a beta of 0.85. The business’s 50 day moving average is $6.71 and its two-hundred day moving average is $7.29. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was up 147.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.43) earnings per share. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now directly owns 7,109,875 shares in the company, valued at $48,631,545. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 119,235 shares of company stock worth $802,988 over the last ninety days. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently bought and sold shares of RXRX. Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after acquiring an additional 288,926 shares in the last quarter. FMR LLC grew its stake in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after buying an additional 170,810 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $5,769,000. Pier 88 Investment Partners LLC grew its position in Recursion Pharmaceuticals by 442.1% in the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock worth $882,000 after acquiring an additional 109,210 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of Recursion Pharmaceuticals by 6,439.6% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.